BlackJack3D Gossamer Bio (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company with a pipeline of one drug: Seralutinib. Seralutinib is focused on treating pulmonary arterial hypertension ("PAH") and pulmonary hypertension with interstitial lung disease ("PH-ILD"). The company has a history of disappointing investors, typical in biotech, as 90% of drugs fail clinical trials. This is what Gossamer's pipeline looked like in 2020: Harrow's Ophthalmic Pharmaceutical Brands ILEVRO. IOPIDINE 1% OPIDINE 0.5 ...